兒童生長激素缺乏症市場－全球產業規模、佔有率、趨勢、機會及預測（按類型、產品、應用、藥物、分銷管道、地區和競爭格局分類），2021-2031年

全球兒童生長激素缺乏症市場預計將從 2025 年的 40.2 億美元成長到 2031 年的 67.2 億美元，複合年成長率為 8.94%。

該市場專注於提供重組人體生長荷爾蒙療法，用於治療由內源性荷爾蒙缺乏引起的兒童生長遲緩。推動這一成長的關鍵因素包括診斷工具的進步，使得疾病的早期檢測成為可能，以及全球對身高相關發展障礙的認知不斷提高。此外，已開發國家的政府健保報銷政策穩定了患者取得這些重要生物製藥製劑的途徑，從而促進了不依賴新產品上市的穩定需求。

儘管存在這些成長要素，但由於缺乏能夠開立和監測這些複雜治療方法的專業醫療保健人員，該行業仍面臨著巨大的障礙。根據美國小兒科預測，到2024年，醫療保健提供者的密度仍將極低，美國每10萬名兒童中大約只有兩名兒童內分泌科醫生。這種專家短缺嚴重阻礙了患者的診斷和治療啟動，可能限制目標患者群體的擴大，並阻礙市場的廣泛滲透。

市場促進因素

長效生長激素製劑的商業化代表市場的重大變革，有效解決了每日注射帶來的依從性問題。這些先進的生物製藥將給藥頻率降低至每週一次，顯著改善了患者的生活品質和治療效果，因此迅速被兒童患者所接受。領先創新者的財務成功也印證了這項轉變的影響。例如，Ascendis Pharma在2024年11月發布的「2024年第三季財務業績」中宣布，其長效Somatropin製劑Skytropha的銷售額達到4720萬歐元，顯示市場對此便捷治療方法的強烈偏好。同時，兒童生長激素缺乏症盛行率的不斷上升，以及診斷篩檢技術的進步，正在擴大目標患者群體。人們對身高相關疾病的認知不斷提高，促使早期療育，世界反興奮劑機構（WADA）於2024年5月發布的《醫生指南－生長激素缺乏症》也支持了這一趨勢。該指南估計，兒童中該疾病的盛行率在1/4000至1/10000之間。因此，大型製藥公司業務成長強勁。諾和諾德2024年年度報告顯示，其罕見內分泌疾病部門2024年的銷售額成長了31%，這主要得益於全球對這些重要療法的持續需求。

市場挑戰

全球兒童生長激素缺乏症市場面臨的主要結構性障礙是專業醫療人員短缺，尤其是兒童內分泌科醫師。由於這些生物療法需要精確的劑量調整、嚴格的安全監測以及由認證的專科醫生進行持續管理，因此市場的潛在規模不僅受疾病盛行率的限制，也受持證醫療專業人員數量有限的限制。如果專科醫生的供應無法滿足患者的需求，則可能導致診斷瓶頸和等待時間延長，使患者錯過有效生長激素治療干預的關鍵生物學窗口期。由於無法補充專科醫生的供應，這項挑戰進一步加劇，威脅著未來的市場滲透。根據美國小兒科會2025年的報告顯示，兒童內分泌專科醫師培訓計畫的招滿率僅48.1%，超過一半的訓練職缺。新進者數量嚴重不足表明，儘管處方醫生短缺問題日益嚴重，疾病意識不斷提高，但患者的就醫途徑將進一步受到限制，潛在的收入成長也將受到阻礙。

市場趨勢

智慧互聯設備在藥物依從性監測中的應用，透過在家庭和醫療服務提供者之間建立直接的數位連接，正在改變病患照護模式。支援藍牙功能的自動注射器能夠即時傳輸劑量數據，使臨床醫生無需等待預約，即可立即解決依從性問題。這種互聯互通顯著改善了治療效果。根據2025年5月出版的《內分泌學摘要》（Endocrine Abstracts）雜誌，一項關於數位健康平台影響的研究發現，在積極開展數位化服務的診所接受治療的患者，其藥物依從率達到了88%。透過遠端監測，這些技術降低了因漏服藥物而導致的生長遲緩風險。同時，人工智慧的應用正透過預測性治療建模推動市場朝向精準醫療發展。機器學習演算法能夠分析臨床變數並預測個別生長反應，從而減少醫療產業對試驗誤給藥方式的依賴。正如 2025 年 5 月《韓國生物醫學評論》中所述，LG 化學的新型 AI 模型能夠以 98% 的準確率預測兒童的生長激素反應，使內分泌學家能夠為最有可能受益的患者量身定做治療方法。

目錄

第1章概述

第2章調查方法

第3章執行摘要

第4章：客戶評價

第5章 全球兒童生長激素缺乏症市場展望

• 市場規模及預測
  • 按金額
• 市佔率及預測
  • 依類型（先天性生長激素缺乏症、後天性生長激素缺乏症、特發性生長激素缺乏症）
  • 依產品（粉末、溶劑）
  • 用途（生長激素缺乏症、原發性矮小症、透納氏症、胎齡低出生體重、普拉德-威利症候群等）
  • 依藥物類型（Genotropin、Humatrop、Norditropin FlexPro 等）
  • 按分銷管道（醫院藥房、零售藥房、網路藥房、其他）
  • 按地區
  • 按公司（2025 年）
• 市場地圖

6. 北美兒童生長激素缺乏症市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國家分析
  • 美國
  • 加拿大
  • 墨西哥

7. 歐洲兒童生長激素缺乏症市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國家分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

8. 亞太地區兒童生長激素缺乏症市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國家分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

9. 中東和非洲兒童生長激素缺乏症市場展望

• 市場規模及預測
• 市佔率及預測
• 中東和非洲：國家分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

10. 南美洲兒童生長激素缺乏症市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國家分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章 市場動態

• 促進要素
• 任務

第12章 市場趨勢與發展

• 併購
• 產品發布
• 最新進展

第13章 全球兒童生長激素缺乏症市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的可能性
• 供應商電力
• 顧客權力
• 替代品的威脅

第15章 競爭格局

• Novo Nordisk A/S
• Eli Lily and Company
• Novartis AG
• Merck KgaA
• Pfizer Inc.
• Ferring BV
• Genentech Inc
• BioParteners GmbH
• LG Chem Ltd.
• Ipsen SA

第16章 策略建議

第17章：關於研究公司及免責聲明

The Global Pediatric Growth Hormone Deficiency Market is projected to expand from USD 4.02 Billion in 2025 to USD 6.72 Billion by 2031, reflecting a CAGR of 8.94%. This market focuses on providing recombinant human growth hormone therapies to treat somatic growth failure in children resulting from insufficient endogenous hormone secretion. Key drivers propelling this trajectory include advancements in diagnostic tools that facilitate earlier disease detection and a rising global awareness regarding height-related developmental disorders. Additionally, supportive government reimbursement initiatives in developed nations help stabilize patient access to these vital biologic treatments, fostering steady demand independent of new formulation trends.

Despite these growth factors, the industry faces a substantial obstacle due to the shortage of specialized healthcare providers necessary to prescribe and monitor these complex therapies. According to the American Academy of Pediatrics, workforce density remained critically low in 2024, with approximately 2.0 pediatric endocrinologists for every 100,000 children in the United States. This scarcity of specialists creates significant bottlenecks in patient diagnosis and the initiation of treatment, thereby limiting the expansion of the addressable patient population and potentially impeding broader market penetration.

Market Driver

The commercialization of long-acting growth hormone formulations marks a significant evolution in the market, effectively resolving the historical issue of non-adherence linked to daily injection schedules. By lowering administration frequency to once-weekly doses, these advanced biologics notably enhance patient quality of life and treatment results, leading to rapid adoption within pediatric populations. The financial success of key innovators underscores the impact of this shift; for instance, Ascendis Pharma reported in their 'Third Quarter 2024 Financial Results' in November 2024 that revenue for Skytrofa, a long-acting lonapegsomatropin, hit €47.2 million, indicating a strong preference for these more convenient therapies. Concurrently, the rising prevalence of pediatric growth hormone deficiency combined with better diagnostic screening is widening the addressable patient base. Heightened awareness of height-related disorders is driving earlier intervention, a trend supported by the World Anti-Doping Agency's 'Physician Guidelines - Growth Hormone Deficiency' from May 2024, which estimates the condition's prevalence between 1:4000 and 1:10,000 children. Consequently, major pharmaceutical companies are seeing robust growth; Novo Nordisk's 'Annual Report 2024' highlighted a 31% increase in sales within their rare endocrine disorders division in 2024, largely fueled by the sustained global demand for these essential treatments.

Market Challenge

A primary structural barrier hindering the Global Pediatric Growth Hormone Deficiency Market is the shortage of specialized healthcare providers, specifically pediatric endocrinologists. Because these biological therapies necessitate precise dosage titration, strict safety monitoring, and ongoing management by certified specialists, the market's potential volume is capped by the limited capacity of the authorized workforce rather than solely by disease prevalence. When the supply of specialists cannot meet patient demand, it results in diagnostic bottlenecks and extended wait times, potentially causing patients to miss the critical biological windows necessary for effective growth hormone intervention. This challenge is exacerbated by a failure to replenish the specialist pipeline, posing a threat to future market penetration. As reported by the American Academy of Pediatrics in 2025, the pediatric endocrinology fellowship fill rate stood at only 48.1%, leaving over half of the training positions vacant. This significant shortfall in new entrants suggests that the prescriber shortage will intensify, further restricting patient access and limiting revenue scalability despite increasing disease awareness.

Market Trends

The incorporation of connected smart devices for adherence monitoring is transforming patient management by creating a direct digital link between families and healthcare providers. Bluetooth-enabled auto-injectors now transmit dosing data in real-time, enabling clinicians to address compliance issues immediately rather than waiting for scheduled visits. This connectivity notably enhances therapeutic results; according to 'Endocrine Abstracts' in May 2025, in a study on the impact of digital health platforms, patients managed by clinics with active digital engagement attained an optimal adherence rate of 88%. By enabling remote oversight, these technologies reduce the risk of growth failure due to missed doses. Simultaneously, the application of Artificial Intelligence is steering the market toward precision medicine through predictive treatment modeling. Machine learning algorithms are analyzing clinical variables to forecast individual growth responses, reducing the industry's reliance on trial-and-error dosing. As highlighted by 'Korea Biomedical Review' in May 2025, LG Chem's new AI model predicted child growth hormone responses with 98% accuracy, allowing endocrinologists to tailor therapies specifically to patients most likely to benefit.

Key Market Players

• Novo Nordisk A/S
• Eli Lily and Company
• Novartis AG
• Merck KgaA
• Pfizer Inc.
• Ferring B.V
• Genentech Inc
• BioParteners GmbH
• LG Chem Ltd.
• Ipsen S.A.

Report Scope

In this report, the Global Pediatric Growth Hormone Deficiency Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Pediatric Growth Hormone Deficiency Market, By Type

• Congenital GH Deficiency
• Acquired GH Deficiency
• Idiopathic GH Deficiency

Pediatric Growth Hormone Deficiency Market, By Product

• Powder
• Solvent

Pediatric Growth Hormone Deficiency Market, By Application

• Growth Hormone Deficiency
• Idiopathic Short Stature
• Turner Syndrome
• Small For Gestational Age
• Prader-Willi Syndrome
• Others

Pediatric Growth Hormone Deficiency Market, By Drug

• Genotropin
• Humatrope
• Norditropin Flexpro
• Others

Pediatric Growth Hormone Deficiency Market, By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Others

Pediatric Growth Hormone Deficiency Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Pediatric Growth Hormone Deficiency Market.

Available Customizations:

Global Pediatric Growth Hormone Deficiency Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Pediatric Growth Hormone Deficiency Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type (Congenital GH Deficiency, Acquired GH Deficiency, Idiopathic GH Deficiency)
  • 5.2.2. By Product (Powder, Solvent)
  • 5.2.3. By Application (Growth Hormone Deficiency, Idiopathic Short Stature, Turner Syndrome, Small For Gestational Age, Prader-Willi Syndrome, Others)
  • 5.2.4. By Drug (Genotropin, Humatrope, Norditropin Flexpro, Others)
  • 5.2.5. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Others)
  • 5.2.6. By Region
  • 5.2.7. By Company (2025)
• 5.3. Market Map

6. North America Pediatric Growth Hormone Deficiency Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Product
  • 6.2.3. By Application
  • 6.2.4. By Drug
  • 6.2.5. By Distribution Channel
  • 6.2.6. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Pediatric Growth Hormone Deficiency Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Product
      • 6.3.1.2.3. By Application
      • 6.3.1.2.4. By Drug
      • 6.3.1.2.5. By Distribution Channel
  • 6.3.2. Canada Pediatric Growth Hormone Deficiency Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Product
      • 6.3.2.2.3. By Application
      • 6.3.2.2.4. By Drug
      • 6.3.2.2.5. By Distribution Channel
  • 6.3.3. Mexico Pediatric Growth Hormone Deficiency Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Product
      • 6.3.3.2.3. By Application
      • 6.3.3.2.4. By Drug
      • 6.3.3.2.5. By Distribution Channel

7. Europe Pediatric Growth Hormone Deficiency Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By Product
  • 7.2.3. By Application
  • 7.2.4. By Drug
  • 7.2.5. By Distribution Channel
  • 7.2.6. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Pediatric Growth Hormone Deficiency Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Product
      • 7.3.1.2.3. By Application
      • 7.3.1.2.4. By Drug
      • 7.3.1.2.5. By Distribution Channel
  • 7.3.2. France Pediatric Growth Hormone Deficiency Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Product
      • 7.3.2.2.3. By Application
      • 7.3.2.2.4. By Drug
      • 7.3.2.2.5. By Distribution Channel
  • 7.3.3. United Kingdom Pediatric Growth Hormone Deficiency Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Product
      • 7.3.3.2.3. By Application
      • 7.3.3.2.4. By Drug
      • 7.3.3.2.5. By Distribution Channel
  • 7.3.4. Italy Pediatric Growth Hormone Deficiency Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type
      • 7.3.4.2.2. By Product
      • 7.3.4.2.3. By Application
      • 7.3.4.2.4. By Drug
      • 7.3.4.2.5. By Distribution Channel
  • 7.3.5. Spain Pediatric Growth Hormone Deficiency Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type
      • 7.3.5.2.2. By Product
      • 7.3.5.2.3. By Application
      • 7.3.5.2.4. By Drug
      • 7.3.5.2.5. By Distribution Channel

8. Asia Pacific Pediatric Growth Hormone Deficiency Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Product
  • 8.2.3. By Application
  • 8.2.4. By Drug
  • 8.2.5. By Distribution Channel
  • 8.2.6. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Pediatric Growth Hormone Deficiency Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Product
      • 8.3.1.2.3. By Application
      • 8.3.1.2.4. By Drug
      • 8.3.1.2.5. By Distribution Channel
  • 8.3.2. India Pediatric Growth Hormone Deficiency Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Product
      • 8.3.2.2.3. By Application
      • 8.3.2.2.4. By Drug
      • 8.3.2.2.5. By Distribution Channel
  • 8.3.3. Japan Pediatric Growth Hormone Deficiency Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Product
      • 8.3.3.2.3. By Application
      • 8.3.3.2.4. By Drug
      • 8.3.3.2.5. By Distribution Channel
  • 8.3.4. South Korea Pediatric Growth Hormone Deficiency Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type
      • 8.3.4.2.2. By Product
      • 8.3.4.2.3. By Application
      • 8.3.4.2.4. By Drug
      • 8.3.4.2.5. By Distribution Channel
  • 8.3.5. Australia Pediatric Growth Hormone Deficiency Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type
      • 8.3.5.2.2. By Product
      • 8.3.5.2.3. By Application
      • 8.3.5.2.4. By Drug
      • 8.3.5.2.5. By Distribution Channel

9. Middle East & Africa Pediatric Growth Hormone Deficiency Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Product
  • 9.2.3. By Application
  • 9.2.4. By Drug
  • 9.2.5. By Distribution Channel
  • 9.2.6. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Pediatric Growth Hormone Deficiency Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Product
      • 9.3.1.2.3. By Application
      • 9.3.1.2.4. By Drug
      • 9.3.1.2.5. By Distribution Channel
  • 9.3.2. UAE Pediatric Growth Hormone Deficiency Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Product
      • 9.3.2.2.3. By Application
      • 9.3.2.2.4. By Drug
      • 9.3.2.2.5. By Distribution Channel
  • 9.3.3. South Africa Pediatric Growth Hormone Deficiency Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Product
      • 9.3.3.2.3. By Application
      • 9.3.3.2.4. By Drug
      • 9.3.3.2.5. By Distribution Channel

10. South America Pediatric Growth Hormone Deficiency Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type
  • 10.2.2. By Product
  • 10.2.3. By Application
  • 10.2.4. By Drug
  • 10.2.5. By Distribution Channel
  • 10.2.6. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Pediatric Growth Hormone Deficiency Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type
      • 10.3.1.2.2. By Product
      • 10.3.1.2.3. By Application
      • 10.3.1.2.4. By Drug
      • 10.3.1.2.5. By Distribution Channel
  • 10.3.2. Colombia Pediatric Growth Hormone Deficiency Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type
      • 10.3.2.2.2. By Product
      • 10.3.2.2.3. By Application
      • 10.3.2.2.4. By Drug
      • 10.3.2.2.5. By Distribution Channel
  • 10.3.3. Argentina Pediatric Growth Hormone Deficiency Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type
      • 10.3.3.2.2. By Product
      • 10.3.3.2.3. By Application
      • 10.3.3.2.4. By Drug
      • 10.3.3.2.5. By Distribution Channel

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Pediatric Growth Hormone Deficiency Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Novo Nordisk A/S
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Eli Lily and Company
• 15.3. Novartis AG
• 15.4. Merck KgaA
• 15.5. Pfizer Inc.
• 15.6. Ferring B.V
• 15.7. Genentech Inc
• 15.8. BioParteners GmbH
• 15.9. LG Chem Ltd.
• 15.10. Ipsen S.A.

16. Strategic Recommendations

17. About Us & Disclaimer